To evaluate the efficacy/safety of osimertinib prior to CRT and maintenance of it with Stage III, unresectable NSCLC with EGFR mutations

Trial Identifier: D516AC00003
Sponsor: AstraZeneca
Start Date: April 2024
Primary Completion Date: July 2026
Study Completion Date: July 2027
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing Shi, CN, 100021
CN Changsha, CN, 410013
CN Guangzhou, CN, 510060
CN Hangzhou, CN, 310022
CN Harbin, CN, 150081
CN Hefei, CN, 230001
CN Jinan, CN, 250117
CN Nanning, CN, 530021
CN Shanghai, CN, 200032
CN Tianjin Shi, CN, 300060
CN Wuhan, CN, 430071
CN Wuhan, CN, 430022
CN Zhengzhou, CN, 450052
ES Barcelona, ES, 08003
ES Donostia-San Sebastian, ES, 20014
ES Granada, ES, 18016
ES Madrid, ES, 28007
IL Haifa, IL, 31096
IL Jerusalem, IL, 91031
IL Tel Aviv, IL, 62748
KR Cheongju-si, KR, 28644
KR Seongnam-si, KR, 13620
KR Seoul, KR, 03080
KR Seoul, KR, 03722
KR Seoul, KR, 06351
KR Suwon, KR, 16247
TH Bangkok, TH, 10210
TH Bangkok, TH, 10330
TH Chiang Rai, TH, 57000
TH Hat Yai, TH, 90110
TH Khon Kaen, TH, 40002
TR Ankara, TR, 06010
TR Yenimahalle, TR, 06560
TW Tainan, TW, 704
TW Taipei, TW, 11217
US, CA La Jolla, CA, US, 92093
US, CA Palo Alto, CA, US, 94304
VN Hanoi, VN, 100000
VN Ho Chi Minh, VN, 700000